A Phase 1 Study of AV-380 in Healthy Subjects

A Phase 1, First-in-human, Randomized, Placebo Controlled, Double Blind, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AV-380 in Healthy Subjects

This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Study Overview

• Status: Completed
• Conditions: Cachexia
• Intervention / Treatment: Drug: AV-380; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 51
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Newark, New Jersey, United States, 07103
      • Biotrial Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 48 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy male and female volunteers, 18 to 50 years of age, inclusive.
2. A body mass index (BMI) between 18 and 30 kg/m2 and weight between 60 and 90 kg.
3. Healthy as indicated by a comprehensive clinical assessment (detailed medical history and complete physical examination). Supine blood pressure (BP), heart rate (HR), electrocardiogram (ECG) intervals and routine laboratory tests within the normal range of the study center (see Appendix 4) or considered not clinically significant by the Investigator. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin must be < 1.5 times the upper limit of the normal range (ULN). Total bilirubin, if above 1.5 x ULN, is only acceptable with a history of Gilbert's Syndrome.
4. Non-smoker or ex-smoker for longer than 6 months.
5. Sexually active pre-menopausal female subjects and female partners of male subjects must use adequate contraceptive measures, while on study and for at least 100 days after the IMP administration. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 160 days after the last dose of IMP. All fertile male and female subjects and their partners must agree to use a highly effective method of contraception. Effective birth control includes hormonal contraception (oral, intravaginal, transdermal, injectable or implantable), intrauterine device (IUD) plus one barrier method; or 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). Vasectomy (at least 3 months before IMP administration) and vasectomized partner (provided that the partner is the sole sexual partner of the trial participant and that the absence of sperm in the ejaculate has been confirmed) are acceptable methods of contraception, as well as post-menopausal female for at least 1 year (confirmed with serum follicle stimulating hormone [FSH] > 25.8 IU/L at screening), or surgically sterilized female subjects. Abstinence is not an acceptable contraception method. Female subjects who are of non-childbearing potential due to a surgical procedure or medical condition must provide documentation, and vasectomized male subjects must bring in the surgical report of the procedure.
6. Able to sign and understand an ICF and able to comply with study restrictions prior to selection.

Exclusion Criteria:

1. Presence or history of any disorder that may prevent the successful completion of the study.

2. Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), such as:

   • White blood cell count < 3.0x109/L.
   • Neutrophils < 1.5x109/L or clinically abnormal according to the subject's ethnic group (must be > 1.0x109/L for subjects of African descent).
   • Hemoglobin < 10 g/dL.
   • Platelet count < 125x109/L or > 450x109/L.
   • ALT > 1.5 ULN.
   • AST > 1.5 ULN.
   • Total bilirubin > 1.5 ULN (except in the presence of Gilbert's syndrome).
   • Creatinine > 1.2 ULN.
   • Sodium < 132 mmol/L or > 147 mmol/L.
   • Potassium < 3.2 mmol/L or > 5.5 mmol/L.
   • Chloride < 93 mmol/L or > 111 mmol/L.
   • Calcium < 8.3 mmol/L or > 10.7 mmol/L. Clinically significant abnormal values for all other laboratory parameters are at the investigator's discretion.
3. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the investigational medicine product.
4. Any history of drug related hypersensitivity reaction.
5. Prior treatment with a monoclonal antibody.
6. Intercurrent illness as evidenced by, e.g., nausea, vomiting, fever, or diarrhea) within 7 days before D1.
7. History of drug abuse (habitual taking of addictive or illegal drugs) within 1 year before D1.
8. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or grapefruit-containing products or alcoholic beverages within 48 hours before D1 and until D7.
9. Any condition or disease detected during the medical interview / physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator or his designee.
10. Frequent headaches and/or migraine, recurrent nausea and / or vomiting.
11. Female subjects who are pregnant, or breastfeeding.
12. Positive screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine [PCP]) and breath alcohol test at screening or D-2.
13. Positive serology for hepatitis B or hepatitis C or human immunodeficiency viruses (HIV).
14. Positive SARS-CoV-2 RT-PCR.
15. Any condition detected at screening that may interfere with or bias the physical examinations to be performed during the study.
16. Any prescribed or over-the-counter medication or herbal products taken within 1 week prior to start of administration of IMP (D1) or within 6 times the elimination half-life of the medication prior to start of IMP intake (whichever is longer), except birth control as described in inclusion criterion number 5 in Section 6.1. Vitamin/mineral supplements and occasional use of acetaminophen is allowed up until 24 hours before dosing.
17. Participation in a clinical trial or use of an investigational drug within 30 days before randomization.
18. Any vaccination within 30 days before signature of informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo is sterile liquid for IV infusion.
Experimental: AV-380 IV 4 mg/kg; IV infusion of AV-380 at dose level 4 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 IV 8 mg/kg; IV infusion of AV-380 at dose level 8 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 IV 13 mg/kg; IV infusion of AV-380 at dose level 13 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 IV 20 mg/kg; IV infusion of AV-380 at dose level 20 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 SC 4 mg/kg; Subcutaneous injection of AV-380 at dose level 4 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 SC 2 mg/kg; Subcutaneous injection of AV-380 at dose level 2 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Experimental: AV-380 SC 1 mg/kg; Subcutaneous injection of AV-380 at dose level 1 mg/kg	Drug: AV-380; AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of adverse events (AEs) and treatment emergent adverse events (TEAEs)		Through study completion, an average of 60 days
Injection site safety and tolerability assessment	Site injection tolerability will be assessed by the Investigator using a 4-level score (none, mild, moderate, severe) after IV infusion and SC injection.	Visit Day 1
Clinical laboratory measurements - Hematology - hemoglobin	Hemoglobin (g/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - hematocrit	Hematocrit (%)	Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - erythrocytes	Erythrocytes	Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - white blood cell count	White blood cell count with differential (neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelets) (X10(3)/UL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - sodium	Sodium (mmol/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - potassium	Potassium (mmol/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - calcium	Calcium (mg/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - chloride	Chloride (mmol/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - CO2	CO2 (mmol/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - blood urea nitrogen	Blood urea nitrogen (mg/dl)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - creatinine	creatinine (mg/dL), glucose, total proteins, triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - glucose	Glucose (mg/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total proteins	Total proteins (g/dL), triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - triglycerides	Triglycerides (mg/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total cholesterol	Total cholesterol (mg/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - AST	AST (U/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - ALT	ALT (U/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - Gamma-glutamyltransferase	Gamma-glutamyltransferase (U/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - Creatinine phosphokinase	Creatinine phosphokinase (mg/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - albumin	Albumin (g/dL)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - alkaline phosphatase	Alkaline phosphatase (U/L)	Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total bilirubin	Total bilirubin (mg/dl)	Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - partial thromboplastin time	Activated partial thromboplastin time (secs)	Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - prothrombin time	Prothrombin time (sec)	Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - International normalized ratio	International normalized ratio	Visits Day 1 through Day 60
Clinical laboratory measurements - Hormonology	Measured parameters: Hormonology (TSH, FSH (for post-menopausal women); β-HCG (for women of childbearing potential))	Visits Day 1 through Day 90
Clinical laboratory measurements - Hormonology - TSH	TSH (mIU/mL)	Visits Day 1 through Day 90
Clinical laboratory measurements - Hormonology - FSH	FSH (mIU/mL)	Visits Day 1 through Day 90
Clinical laboratory measurements - Urinalysis - pH	pH	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - protein	Protein (negative/positive)	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - glucose	Glucose (negative/positive)	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - leukocytes	Leukocytes (negative/positive)	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - nitrites	Nitrites (negative/positive)	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - ketones	Ketones (negative/positive)	Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - blood	Blood (negative/positive)	Visits Day 1 through Day 60
Vital signs measurements - Blood pressure	Supine and standing systolic and diastolic blood pressure (mmHg)	Visits Day 1 through Day 90
Vital signs measurements - Heart rate	Heart rate (beats/min)	Visits Day 1 through Day 90
Vital signs measurements - Body temperature	Body temperature (degrees Celsius)	Visits Day 1 through Day 90
Vital signs measurements - Respiratory rate	Respiratory rate (breaths/min)	Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - Mean heart rate	ECG mean heart rate (beats/min)	Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - PR interval	PR interval, aggregate (msec)	Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - QRS axis	QRS axis (deg)	Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - QTcF interval	QTcF interval, aggregate (msec)	Visits Day 1 through Day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection	Cmax (maximum observed serum concentration)	Visits Day 1 through D90
Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection	Tmax (time to reach maximum serum concentration)	Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380	Emax (maximum effect observed)	Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380	AUEC (area under the effect-time curve)	Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380	TEmax (time to reach maximum effect)	Visits Day 1 through Day 90
AV-380 immunogenicity in healthy subjects - anti-AV-380 antibodies (human anti-human antibodies [HAHA]) levels in serum.	HAHA levels	Visits Day 1 through Day 180
AV-380 immunogenicity in healthy subjects - Monocyte chemoattractant protein 1 (MCP-1) levels in serum.	Serum MCP-1 levels will be measured.	Visits Day 1 and Day 2

Collaborators and Investigators

• Sponsor: AVEO Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2021
• Primary Completion (Actual): January 14, 2022
• Study Completion (Actual): January 14, 2022

Study Registration Dates

• First Submitted: March 8, 2021
• First Submitted That Met QC Criteria: March 22, 2021
• First Posted (Actual): March 25, 2021

Study Record Updates

• Last Update Posted (Actual): June 12, 2023
• Last Update Submitted That Met QC Criteria: June 8, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Body Weight; Body Weight Changes; Weight Loss; Thinness; Cachexia
• Other Study ID Numbers: AV-380-20-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No